EGFR and neoplasm: The TRACERx study revealed that metastatic lesions often harbour unique mutations not found in primary tumours, but only 33% of these are driver mutations, affecting genes like TP53, KMT2D, STK11, SMARCA4, FAT1, NF1, RBM10, PIK3CA, ARID1A, CUX1, FBXW7, EGFR, ARHGAP35 [120].